X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New data from insurers show detriments of copay accumulator adjustment programs

By Katie Koziara  |    April 28, 2021
Commercial health insurers are starting to admit what the biopharmaceutical research industry has been warning for some time: copay accumulator adjustment programs hurt patient outcomes and shift...   Read More

Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter

By Katie Koziara  |    March 2, 2021
A new study published in Health Affairs finds that for nearly 40% of commercially insured patients, half of their annual out-of-pocket expenses for medical treatments come from just one hospital,...   Read More

Insurers shift medicine costs to patients with severe chronic illnesses

By Gabby Migliara  |    February 1, 2021
For many patients with complex and chronic conditions, high out-of-pocket costs for medicines pose a significant challenge. Recent research revealed a broken insurance system that fails to help...   Read More

The new Administration should reconsider a recent HHS rule that could negatively impact patient access and affordability

By Gabby Migliara  |    January 27, 2021
On January 14, the Department of Health & Human Services’ (HHS) released the 2022 Notice of Benefit and Payment Parameters (NBPP) final rule. Several provisions of the final rule promote access to...   Read More

New insulin report highlights how incentives benefit middlemen, harm patients

By Brian Newell  |    January 22, 2021
The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...   Read More

New data show retail medicine prices fell in 2019

By Katie Koziara  |    January 13, 2021
In 2019, retail prescription medicine prices declined by 0.4%, on average, according to National Health Expenditures (NHE) data from the Centers for Medicare & Medicaid Services (CMS) published...   Read More

Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds

By Gabby Migliara  |    November 19, 2020
A new analysis by IQVIA looked at three cost-sharing assistance programs and found that from 2018 to 2020, 25% to 36% of patients discontinued treatment when they faced an unexpectedly high...   Read More

Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015

By Gabby Migliara  |    October 21, 2020
Medicines are responsible for more than a third of the improvement in life expectancy from 1990 to 2015, according to a recent study published in Health Affairs. This underscores the crucial role...   Read More

Survey found insurance premiums grew faster than inflation in 2020

By Gabby Migliara  |    October 20, 2020
According to Kaiser Family Foundation’s recent survey on employer health benefits, premiums for people with employer-sponsored health insurance increased by 4% last year, faster than both the rate...   Read More

Study finds middlemen excluded nearly 850 medicines from formularies this year

By Katie Koziara  |    September 17, 2020
A new study from Xcenda finds that from 2014 to 2020, the number of medicines excluded by at least one of the three largest pharmacy benefit managers (PBMs) from their standard formularies...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates